The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
The SCOPE project aimed to better understand practice patterns, identify drivers for treatment goals, and determine third- and fourth-line treatment choices for patients with metastatic colorectal cancer (mCRC). The survey was developed by an expert panel of gastrointestinal oncologists. Questions c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/3/194 |
| _version_ | 1797520712989147136 |
|---|---|
| author | Gerald Prager Claus-Henning Köhne Juan Manuel O’Connor Fernando Rivera Daniele Santini Harpreet Wasan Jean Marc Phelip |
| author_facet | Gerald Prager Claus-Henning Köhne Juan Manuel O’Connor Fernando Rivera Daniele Santini Harpreet Wasan Jean Marc Phelip |
| author_sort | Gerald Prager |
| collection | DOAJ |
| description | The SCOPE project aimed to better understand practice patterns, identify drivers for treatment goals, and determine third- and fourth-line treatment choices for patients with metastatic colorectal cancer (mCRC). The survey was developed by an expert panel of gastrointestinal oncologists. Questions concerned general practice patterns, and treatment decisions for three hypothetical patient case scenarios. Participants had to routinely manage patients with mCRC. We present results from 629 participants who provided input on patient treatment scenarios (data cutoff: 17/01/2020). Prolonging overall survival (OS; 51%) was the main aim in first line. In third line, quality of life (QOL) was the primary goal (34%). Forty-three percent also cited efficacy-focused goals; 18% and 13% noted prolonging OS and improving progression-free survival as main aims, respectively. For fit and active patients, 89% of respondents considered trifluridine-tipiracil an appropriate third-line treatment; regorafenib (31%) or clinical trial enrollment (29%) were the fourth-line options. For patients with comorbidities and limited caregiver support, trifluridine-tipiracil was the preferred third-line treatment (70%). For <i>KRAS</i>-mutated patients with comorbidities and adverse events who received prior oxaliplatin, 90% considered oxaliplatin rechallenge an unsuitable third-line treatment, mainly due to the risk of cumulative toxicity (75%). In the third/fourth-line settings, trifluridine-tipiracil followed by regorafenib was the most common option (54%); 17% chose regorafenib followed by trifluridine-tipiracil. Efficacy coupled with QOL are important goals in third-line treatment. Daily practice patterns reflect the guideline recommendations in third- and fourth-line settings, with a trend toward using trifluridine-tipiracil versus regorafenib in <i>KRAS</i>-wildtype and <i>KRAS</i>-mutant tumors. |
| first_indexed | 2024-03-10T08:01:30Z |
| format | Article |
| id | doaj.art-e319e34fd9e347e0b2634a2c20338756 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:01:30Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-e319e34fd9e347e0b2634a2c203387562023-11-22T11:30:03ZengMDPI AGCurrent Oncology1198-00521718-77292021-06-012832097210610.3390/curroncol28030194The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRCGerald Prager0Claus-Henning Köhne1Juan Manuel O’Connor2Fernando Rivera3Daniele Santini4Harpreet Wasan5Jean Marc Phelip6Department of Medicine, Medical University of Vienna, 1090 Vienna, AustriaInnere Medizin–Onkologie und Hämatologie, Klinikum Oldenburg, 26133 Oldenburg, GermanyDepartment of Clinical Oncology, Instituto Alexander Fleming, Buenos Aires C1426ANZ, ArgentinaDepartment of Medical Oncology, University Hospital Marqués de Valdecilla, IDIVAL, 39008 Santander, SpainDepartment of Medical Oncology, Policlinico Universitario Campus Bio-Medico Rome, 00128 Rome, ItalyDepartment of Cancer Medicine, Hammersmith Hospital, London SW7 2AZ, UKDepartment of Hepato-Gastroenterology, University Hospital of Saint-Étienne, 42270 Saint-Étienne-Priest-en-Jarez, FranceThe SCOPE project aimed to better understand practice patterns, identify drivers for treatment goals, and determine third- and fourth-line treatment choices for patients with metastatic colorectal cancer (mCRC). The survey was developed by an expert panel of gastrointestinal oncologists. Questions concerned general practice patterns, and treatment decisions for three hypothetical patient case scenarios. Participants had to routinely manage patients with mCRC. We present results from 629 participants who provided input on patient treatment scenarios (data cutoff: 17/01/2020). Prolonging overall survival (OS; 51%) was the main aim in first line. In third line, quality of life (QOL) was the primary goal (34%). Forty-three percent also cited efficacy-focused goals; 18% and 13% noted prolonging OS and improving progression-free survival as main aims, respectively. For fit and active patients, 89% of respondents considered trifluridine-tipiracil an appropriate third-line treatment; regorafenib (31%) or clinical trial enrollment (29%) were the fourth-line options. For patients with comorbidities and limited caregiver support, trifluridine-tipiracil was the preferred third-line treatment (70%). For <i>KRAS</i>-mutated patients with comorbidities and adverse events who received prior oxaliplatin, 90% considered oxaliplatin rechallenge an unsuitable third-line treatment, mainly due to the risk of cumulative toxicity (75%). In the third/fourth-line settings, trifluridine-tipiracil followed by regorafenib was the most common option (54%); 17% chose regorafenib followed by trifluridine-tipiracil. Efficacy coupled with QOL are important goals in third-line treatment. Daily practice patterns reflect the guideline recommendations in third- and fourth-line settings, with a trend toward using trifluridine-tipiracil versus regorafenib in <i>KRAS</i>-wildtype and <i>KRAS</i>-mutant tumors.https://www.mdpi.com/1718-7729/28/3/194metastatic colorectal cancerpractice patternstrifluridine-tipiracilregorafenib<i>KRAS</i>-mutated mCRC<i>KRAS</i>-wildtype mCRC |
| spellingShingle | Gerald Prager Claus-Henning Köhne Juan Manuel O’Connor Fernando Rivera Daniele Santini Harpreet Wasan Jean Marc Phelip The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC Current Oncology metastatic colorectal cancer practice patterns trifluridine-tipiracil regorafenib <i>KRAS</i>-mutated mCRC <i>KRAS</i>-wildtype mCRC |
| title | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC |
| title_full | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC |
| title_fullStr | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC |
| title_full_unstemmed | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC |
| title_short | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC |
| title_sort | screening and consensus based on practices and evidence scope program results of a survey on daily practice patterns for patients with mcrc |
| topic | metastatic colorectal cancer practice patterns trifluridine-tipiracil regorafenib <i>KRAS</i>-mutated mCRC <i>KRAS</i>-wildtype mCRC |
| url | https://www.mdpi.com/1718-7729/28/3/194 |
| work_keys_str_mv | AT geraldprager thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT claushenningkohne thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT juanmanueloconnor thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT fernandorivera thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT danielesantini thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT harpreetwasan thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT jeanmarcphelip thescreeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT geraldprager screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT claushenningkohne screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT juanmanueloconnor screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT fernandorivera screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT danielesantini screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT harpreetwasan screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc AT jeanmarcphelip screeningandconsensusbasedonpracticesandevidencescopeprogramresultsofasurveyondailypracticepatternsforpatientswithmcrc |